Horizon Therapeutics PLC (NASDAQ:HZNP)
| 110.63 Delayed Data As of Jan 27 |  -0.62 / -0.56%Today’s Change | 57.84 Today|||52-Week Range 117.49 | -2.79% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $25.7B |
Company Description
Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.
Contact Information
Horizon Therapeutics Plc 70 St. Stephen's Green Dublin Dublin 4 |
Employees
Shareholders
| Other institutional | 54.51% |
| Mutual fund holders | 49.54% |
| Individual stakeholders | 1.07% |
Top Executives
| Timothy P. Walbert | Chairman, President & Chief Executive Officer |
| Aaron L. Cox | Chief Financial Officer & Executive Vice President |
| Jeffrey W. Sherman | Chief Medical Officer & Executive Vice President |
| Jeffrey D. Kent | Executive VP-Medical Affairs & Outcomes Research |
| Michael A. DesJardin | Executive VP-Technical Operations & Quality |
